Tyr501
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr501  -  SHPS1 (rat)

Site Information
PEPSFSEyASVQVQR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 451115
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 1 ) , immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 ) , mutation of modification site ( 7 ) , phospho-antibody ( 1 , 7 ) , western blotting ( 1 )
Disease tissue studied:
kidney cancer ( 1 )
Relevant cell line - cell type - tissue:
brain ( 2 , 3 , 4 , 5 , 6 ) , CHO (fibroblast) [EphB1 (human), transfection] ( 7 ) , kidney ( 1 )

Upstream Regulation
Phosphatases, in vitro:
SHP-2 (human) ( 7 )
Treatments:
insulin ( 7 )

Downstream Regulation
Effects of modification on SHPS1:
molecular association, regulation ( 7 )
Induce interaction with:
SHP-2 (human) ( 7 )

References 

1

Zhang Y, et al. (2010) Glomerular proteins related to slit diaphragm and matrix adhesion in the foot processes are highly tyrosine phosphorylated in the normal rat kidney. Nephrol Dial Transplant 25, 1785-95
20067908   Curated Info

2

Guo A (2009) CST Curation Set: 5871; Year: 2009; Biosample/Treatment: tissue, brain/No seizure; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

3

Guo A (2005) CST Curation Set: 678; Year: 2005; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

4

Guo A (2005) CST Curation Set: 679; Year: 2005; Biosample/Treatment: tissue, brain/ischemia 15'; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Guo A (2005) CST Curation Set: 531; Year: 2005; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Guo A (2005) CST Curation Set: 522; Year: 2005; Biosample/Treatment: tissue, brain/ischemia; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Takada T, et al. (1998) Roles of the complex formation of SHPS-1 with SHP-2 in insulin-stimulated mitogen-activated protein kinase activation. J Biol Chem 273, 9234-42
9535915   Curated Info